Pharmacoeconomic Analysis Of Afatinib As 1st-Line Treatment Of Metastatic Non-Small Cell Lung Cancer With Del19 Mutation Of Egfr Gene

Nov 1, 2015, 00:00 AM
10.1016/j.jval.2015.09.1180
https://www.valueinhealthjournal.com/article/S1098-3015(15)03256-8/fulltext
Section Title : Research Podium Presentations - Session 1 and Session 2
Section Order : 678
First Page : A458
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03256-8&doi=10.1016/j.jval.2015.09.1180
HEOR Topics :
Tags :
Regions :